---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061288"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:26:40.003193+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Soleno reports Q4 net loss $11.3M; NDA for DCCR in PWS on track for mid-2024

## Summary
- Cash and equivalents $169.7M at Dec 31, 2023, boosted by $129M Oct 2023 offering and $43.1M warrant exercises.
- R&D expenses rose to $8.7M (Q4 2023) vs $3.8M (Q4 2022); full-year $25.2M vs $15.3M.
- Corrected G&A for Q4 2023: $4.1M vs previously reported $4.4M; full-year $13.5M vs $9.8M.
- Positive top-line data from C602 withdrawal: primary endpoint met (p=0.0022); DCCR well-tolerated.
- Leadership additions: Meredith Manning as CCO, Dairine Dempsey VP Europe, Lauren Budesheim VP HR.

## SEC filing metadata
- accession: 0001193125-24-061288
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/0001193125-24-061288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/d764812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061288
- JSON: https://secwatch.observer/filing/0001193125-24-061288.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061288.txt

## Key facts
- Earnings Releases
  SOLENO THERAPEUTICS INC reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was approximately $11.3 million, or $0.33 per basic and diluted share, for the quarter ended December 31, 2023,, EPS $0.33 per basic and diluted share (Q4 2023); $2.36 per basic and diluted share (FY 2023).
  - Period: the fourth quarter and year ended December 31, 2023
  - Net income: Net loss was approximately $11.3 million, or $0.33 per basic and diluted share, for the quarter ended December 31, 2023,
  - EPS: $0.33 per basic and diluted share (Q4 2023); $2.36 per basic and diluted share (FY 2023)
  - Result: reported results
  source text: Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/0001193125-24-061288-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.